Work

Real‐world treatment burden of brentuximab vedotin‐based front‐line regimens in young adults and adults with advanced‐stage classical Hodgkin lymphoma

Year: 2026
Type: article
Abstract: Real-world treatment burden of brentuximab vedotin-based frontline regimens in young adults and adults with advanced-stage classical Hodgkin lymphomaTo the Editor, We read with great enthusiasm the multicentre, retrospective study by Porges et al. in British Journal of Haematology in August 2026, 1 assessing front-line brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD) in 100 advanced-stage classical Hodgkin lymphoma (cHL) patients (median age, 30 years).The outstanding disease control reported by the
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $5,190
OpenAlex ID: W7236701555
FWCI: 4.234
Cites: 7
Cited by: 1
Related to: 10